Literature DB >> 26276628

The Brain on Drugs: From Reward to Addiction.

Nora D Volkow1, Marisela Morales2.   

Abstract

Advances in neuroscience identified addiction as a chronic brain disease with strong genetic, neurodevelopmental, and sociocultural components. We here discuss the circuit- and cell-level mechanisms of this condition and its co-option of pathways regulating reward, self-control, and affect. Drugs of abuse exert their initial reinforcing effects by triggering supraphysiologic surges of dopamine in the nucleus accumbens that activate the direct striatal pathway via D1 receptors and inhibit the indirect striato-cortical pathway via D2 receptors. Repeated drug administration triggers neuroplastic changes in glutamatergic inputs to the striatum and midbrain dopamine neurons, enhancing the brain's reactivity to drug cues, reducing the sensitivity to non-drug rewards, weakening self-regulation, and increasing the sensitivity to stressful stimuli and dysphoria. Drug-induced impairments are long lasting; thus, interventions designed to mitigate or even reverse them would be beneficial for the treatment of addiction.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26276628     DOI: 10.1016/j.cell.2015.07.046

Source DB:  PubMed          Journal:  Cell        ISSN: 0092-8674            Impact factor:   41.582


  358 in total

1.  Loss of brain graph network efficiency in alcohol dependence.

Authors:  Zsuzsika Sjoerds; Steven M Stufflebeam; Dick J Veltman; Wim Van den Brink; Brenda W J H Penninx; Linda Douw
Journal:  Addict Biol       Date:  2015-12-22       Impact factor: 4.280

Review 2.  Methamphetamine addiction: involvement of CREB and neuroinflammatory signaling pathways.

Authors:  Irina N Krasnova; Zuzana Justinova; Jean Lud Cadet
Journal:  Psychopharmacology (Berl)       Date:  2016-02-12       Impact factor: 4.530

3.  Voluntary oral consumption of Δ9-tetrahydrocannabinol by adolescent rats impairs reward-predictive cue behaviors in adulthood.

Authors:  Lauren C Kruse; Jessica K Cao; Katie Viray; Nephi Stella; Jeremy J Clark
Journal:  Neuropsychopharmacology       Date:  2019-04-10       Impact factor: 7.853

Review 4.  Event-Related Potentials as Biomarkers of Behavior Change Mechanisms in Substance Use Disorder Treatment.

Authors:  Rebecca J Houston; Nicolas J Schlienz
Journal:  Biol Psychiatry Cogn Neurosci Neuroimaging       Date:  2017-09-23

Review 5.  Overlap in the neural circuitry and molecular mechanisms underlying ketamine abuse and its use as an antidepressant.

Authors:  Saurabh S Kokane; Ross J Armant; Carlos A Bolaños-Guzmán; Linda I Perrotti
Journal:  Behav Brain Res       Date:  2020-02-13       Impact factor: 3.332

6.  GDNF and alcohol use disorder.

Authors:  Segev Barak; Somayeh Ahmadiantehrani; Marian L Logrip; Dorit Ron
Journal:  Addict Biol       Date:  2018-05-04       Impact factor: 4.280

7.  Developmental Trajectories of the Orbitofrontal Cortex and Anhedonia in Middle Childhood and Risk for Substance Use in Adolescence in a Longitudinal Sample of Depressed and Healthy Preschoolers.

Authors:  Joan L Luby; Arpana Agrawal; Andy Belden; Diana Whalen; Rebecca Tillman; Deanna M Barch
Journal:  Am J Psychiatry       Date:  2018-03-21       Impact factor: 18.112

8.  Dopamine D1 or D2 receptor-expressing neurons in the central nervous system.

Authors:  Xiaoyan Wei; Tengfei Ma; Yifeng Cheng; Cathy C Y Huang; Xuehua Wang; Jiayi Lu; Jun Wang
Journal:  Addict Biol       Date:  2017-04-24       Impact factor: 4.280

9.  TAAR1 agonists attenuate extended-access cocaine self-administration and yohimbine-induced reinstatement of cocaine-seeking.

Authors:  Jianfeng Liu; Bernard Johnson; Ruyan Wu; Robert Seaman; Jimmy Vu; Qing Zhu; Yanan Zhang; Jun-Xu Li
Journal:  Br J Pharmacol       Date:  2020-05-05       Impact factor: 8.739

Review 10.  Glial cells as therapeutic targets for smoking cessation.

Authors:  Mohit Kumar; Adewale Adeluyi; Erin L Anderson; Jill R Turner
Journal:  Neuropharmacology       Date:  2020-05-24       Impact factor: 5.250

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.